Claims for Patent: 11,034,660

Summary for Patent: 11,034,660

Title:	Hydrazide containing nuclear transport modulators and uses thereof
Abstract:	The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: ##STR00001## or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
Inventor(s):	Sandanayaka; Vincent P. (Northboro, MA), Shacham; Sharon (Newton, MA), McCauley; Dilara (Arlington, MA), Shechter; Sharon (Andover, MA)
Assignee:	Karyopharm Therapeutics Inc. (Newton, MA)
Application Number:	16/696,702
Patent Claims:	1. A method for treating multiple myeloma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound represented by the following structural formula I-3: ##STR00174## or a pharmaceutically acceptable salt thereof and an additional therapeutic agent selected from bortezomib, dexamethasone or a combination thereof. 2. The method of claim 1, wherein the additional therapeutic agent is bortezomib. 3. The method of claim 1, wherein the additional therapeutic agent is dexamethasone. 4. The method of claim 1, wherein the additional therapeutic agent is a combination of bortezomib and dexamethasone. 5. The method of claim 1, wherein the compound of structural formula I-3 and the additional therapeutic agent are administered in separate dosage forms. 6. The method of claim 2, wherein the compound of structural formula I-3 and the additional therapeutic agent are administered in separate dosage forms. 7. The method of claim 3, wherein the compound of structural formula I-3 and the additional therapeutic agent are administered in separate dosage forms. 8. The method of claim 4, wherein the compound of structural formula I-3 and the additional therapeutic agent are administered in separate dosage forms. 9. The method of claim 1, wherein the compound of structural formula I-3 and the additional therapeutic agent are administered at the same time. 10. The method of claim 2, wherein the compound of structural formula I-3 and the additional therapeutic agent are administered in at the same time. 11. The method of claim 3, wherein the compound of structural formula I-3 and the additional therapeutic agent are administered at the same time. 12. The method of claim 4, wherein the compound of structural formula I-3 and the additional therapeutic agent are administered at the same time. 13. The method of any one of claims 1-12, wherein the compound of structural formula I-3 is orally administered.